Clinical Experience With Neoadjuvant IO Therapy in Melanoma
Shared insight on the use of immune checkpoint inhibitors in other patient populations within the skin cancer paradigm, and how lessons may be applied to patients with CSCC.
EP: 1.Cutaneous Squamous Cell Carcinoma: Incidence and Risk Factors
EP: 2.Available Staging Systems for Cutaneous Squamous Cell Carcinoma
EP: 3.Optimal Risk Stratification in Patients With Cutaneous Squamous Cell Carcinoma
EP: 4.Defining Resectability in CSCC
EP: 5.Staging and Risk Stratification’s Impact on Treatment Approach in CSCC
EP: 6.Real World Experience With Resectable Cutaneous Squamous Cell Carcinoma
EP: 7.Evolving Treatment Paradigm of Resectable CSCC
Now Viewing
EP: 8.Clinical Experience With Neoadjuvant IO Therapy in Melanoma
EP: 9.Lessons Learned in Other Cancers and Suggested Endpoints in Future Trials
EP: 10.Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates
EP: 11.CSCC: Translating Cemiplimab Data Into Practice
EP: 12.Other Emerging Treatment Modalities in Cutaneous Squamous Cell Carcinoma
EP: 13.Best Practices in Multidisciplinary Care for CSCC
EP: 14.CSCC: Escalating Therapy for High-risk Patients
EP: 15.Practical Advice on the Evolving Management of CSCC
Related Videos
Related Content
